Alessandro Prestipino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alessandro Prestipino has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
Justus Duyster
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany
3 shared publicationsAnnette Schmitt-Graeff
Department of Pathology, Freiburg University Medical Center, Albert-Ludwigs University, Freiburg, Germany
2 shared publicationsDietmar Pfeifer
Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
2 shared publicationsFrederike A. Hartl
Faculty of Biology, Albert Ludwigs University of Freiburg, Freiburg 79104, Germany
2 shared publicationsGabriele Prinz
Department of Hematology and Oncology, Freiburg University Medical Center, Freiburg, Germany
2 shared publicationsJürgen Finke
Department of Hematology and Oncology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg 79106, Germany
2 shared publications
Latest Publications
- Open Access
- 14 August 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (9) , 100632
High-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells
- 14 August 2023
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 22 (9) , 100632
Open AccessHigh-Throughput Screening and Proteomic Characterization of Compounds Targeting Myeloid-Derived Suppressor Cells
- 6 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (478) , eaav4810
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Genetic changes modulate antitumor immune responses through the PD-1/PD-L1 axis, which should be considered when designing combinatory drug regimens.
- 6 February 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (478) , eaav4810
Clinical implications of tumor-intrinsic mechanisms regulating PD-L1
Genetic changes modulate antitumor immune responses through the PD-1/PD-L1 axis, which should be considered when designing combinatory drug regimens.
- Top Cited Papers
- 21 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (429)
Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2V617F-mutant cells, whereas blockade of JAK2 reduced PD-L1 expression in myeloid JAK2V617F-mutant cells. PD-L1 expression was higher on primary cells isolated from patients with JAK2V617F–myeloproliferative neoplasms (MPNs) compared to healthy individuals and declined upon JAK2 inhibition. JAK2V617F mutational burden, pSTAT3, and PD-L1 expression were highest in primary MPN patient–derived monocytes, megakaryocytes, and platelets. PD-1 (programmed death receptor 1) inhibition prolonged survival in human MPN xenograft and primary murine MPN models. This effect was dependent on T cells. Mechanistically, PD-L1 surface expression in JAK2V617F-mutant cells affected metabolism and cell cycle progression of T cells. In summary, we report that in MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression. The susceptibility of JAK2V617F-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.
- 21 February 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (429)
Top Cited PapersOncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Recent evidence has revealed that oncogenic mutations may confer immune escape. A better understanding of how an oncogenic mutation affects immunosuppressive programmed death ligand 1 (PD-L1) expression may help in developing new therapeutic strategies. We show that oncogenic JAK2 (Janus kinase 2) activity caused STAT3 (signal transducer and activator of transcription 3) and STAT5 phosphorylation, which enhanced PD-L1 promoter activity and PD-L1 protein expression in JAK2V617F-mutant cells, whereas blockade of JAK2 reduced PD-L1 expression in myeloid JAK2V617F-mutant cells. PD-L1 expression was higher on primary cells isolated from patients with JAK2V617F–myeloproliferative neoplasms (MPNs) compared to healthy individuals and declined upon JAK2 inhibition. JAK2V617F mutational burden, pSTAT3, and PD-L1 expression were highest in primary MPN patient–derived monocytes, megakaryocytes, and platelets. PD-1 (programmed death receptor 1) inhibition prolonged survival in human MPN xenograft and primary murine MPN models. This effect was dependent on T cells. Mechanistically, PD-L1 surface expression in JAK2V617F-mutant cells affected metabolism and cell cycle progression of T cells. In summary, we report that in MPN, constitutive JAK2/STAT3/STAT5 activation, mainly in monocytes, megakaryocytes, and platelets, caused PD-L1–mediated immune escape by reducing T cell activation, metabolic activity, and cell cycle progression. The susceptibility of JAK2V617F-mutant MPN to PD-1 targeting paves the way for immunomodulatory approaches relying on PD-1 inhibition.
- 14 April 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (15) , 1930-1939
Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells
Caveolin-1 (Cav-1) is a key organizer of membrane specializations and a scaffold protein that regulates signaling in multiple cell types. We found increased Cav-1 expression in human and murine T cells after allogeneic hematopoietic cell transplantation. Indeed, Cav-1−/− donor T cells caused less severe acute graft-versus-host disease (GVHD) and yielded higher numbers of regulatory T cells (Tregs) compared with controls. Depletion of Tregs from the graft abrogated this protective effect. Correspondingly, Treg frequencies increased when Cav-1−/− T cells were exposed to transforming growth factor-β/T-cell receptor (TCR)/CD28 activation or alloantigen stimulation in vitro compared with wild-type T cells. Mechanistically, we found that the phosphorylation of Cav-1 is dispensable for the control of T-cell fate by using a nonphosphorylatable Cav-1 (Y14F/Y14F) point-mutation variant. Moreover, the close proximity of lymphocyte-specific protein tyrosine kinase (Lck) to the TCR induced by TCR-activation was reduced in Cav-1−/− T cells. Therefore, less TCR/Lck clustering results in suboptimal activation of the downstream signaling events, which correlates with the preferential development into a Treg phenotype. Overall, we report a novel role for Cav-1 in TCR/Lck spatial distribution upon TCR triggering, which controls T-cell fate toward a regulatory phenotype. This alteration translated into a significant increase in the frequency of Tregs and reduced GVHD in vivo. Key Points Cav-1–deficient T cells preferentially differentiate into Tregs, which translates into lower GVHD severity in mice. Reduced TCR:Lck clustering in Cav-1–deficient T cells is responsible for reduced TCR downstream signaling events promoting Treg differentiation.
- 14 April 2016
- Published by American Society of Hematology in Blood
- Vol. 127 (15) , 1930-1939
Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells
Caveolin-1 (Cav-1) is a key organizer of membrane specializations and a scaffold protein that regulates signaling in multiple cell types. We found increased Cav-1 expression in human and murine T cells after allogeneic hematopoietic cell transplantation. Indeed, Cav-1−/− donor T cells caused less severe acute graft-versus-host disease (GVHD) and yielded higher numbers of regulatory T cells (Tregs) compared with controls. Depletion of Tregs from the graft abrogated this protective effect. Correspondingly, Treg frequencies increased when Cav-1−/− T cells were exposed to transforming growth factor-β/T-cell receptor (TCR)/CD28 activation or alloantigen stimulation in vitro compared with wild-type T cells. Mechanistically, we found that the phosphorylation of Cav-1 is dispensable for the control of T-cell fate by using a nonphosphorylatable Cav-1 (Y14F/Y14F) point-mutation variant. Moreover, the close proximity of lymphocyte-specific protein tyrosine kinase (Lck) to the TCR induced by TCR-activation was reduced in Cav-1−/− T cells. Therefore, less TCR/Lck clustering results in suboptimal activation of the downstream signaling events, which correlates with the preferential development into a Treg phenotype. Overall, we report a novel role for Cav-1 in TCR/Lck spatial distribution upon TCR triggering, which controls T-cell fate toward a regulatory phenotype. This alteration translated into a significant increase in the frequency of Tregs and reduced GVHD in vivo. Key Points Cav-1–deficient T cells preferentially differentiate into Tregs, which translates into lower GVHD severity in mice. Reduced TCR:Lck clustering in Cav-1–deficient T cells is responsible for reduced TCR downstream signaling events promoting Treg differentiation.
- 2 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (1) , 103-112
MicroRNA-155–deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation
The successful treatment of acute leukemias with allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft versus host disease (GvHD). Because microRNA-155 (miR-155) regulates activation of the innate immune system, we aimed to determine its function in dendritic cells (DCs) during GvHD in an experimental model. We observed that miR-155 deficiency of the recipient led to improved survival, reduced serum levels of pro inflammatory cytokines, and lower GvHD histopathology scores. Additionally, miR-155-/- bone marrow chimeric mice receiving allo-HCT and miR-155-/- DCs showed that miR-155 deficiency in the DC compartment was responsible for protection from GvHD. Activated miR-155-/- DCs displayed lower expression of various purinergic receptors and impaired migration towards ATP. Microarray analysis of LPS/ATP-stimulated miR-155-/- DCs revealed MAPK pathway dysregulation and reduced inflammasome-associated gene expression. Consistent with this gene expression data, we observed reduced ERK activation, caspase-1 cleavage, and IL-1β production in miR-155-/- DCs. The connection between miR-155 and inflammasome activation was supported by the fact that Nlrp3/miR-155 double knockout allo-HCT recipient mice experienced no increased protection from GvHD compared to Nlrp3-/- recipients. This study indicates that during GvHD, miR-155 promotes DC migration towards sites of ATP release accompanied by inflammasome activation. Inhibiting pro-inflammatory miR-155 by antagomir treatment could help to reduce this complication of allo-HCT.
- 2 July 2015
- Published by American Society of Hematology in Blood
- Vol. 126 (1) , 103-112
MicroRNA-155–deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation
The successful treatment of acute leukemias with allogeneic hematopoietic cell transplantation (allo-HCT) is limited by acute graft versus host disease (GvHD). Because microRNA-155 (miR-155) regulates activation of the innate immune system, we aimed to determine its function in dendritic cells (DCs) during GvHD in an experimental model. We observed that miR-155 deficiency of the recipient led to improved survival, reduced serum levels of pro inflammatory cytokines, and lower GvHD histopathology scores. Additionally, miR-155-/- bone marrow chimeric mice receiving allo-HCT and miR-155-/- DCs showed that miR-155 deficiency in the DC compartment was responsible for protection from GvHD. Activated miR-155-/- DCs displayed lower expression of various purinergic receptors and impaired migration towards ATP. Microarray analysis of LPS/ATP-stimulated miR-155-/- DCs revealed MAPK pathway dysregulation and reduced inflammasome-associated gene expression. Consistent with this gene expression data, we observed reduced ERK activation, caspase-1 cleavage, and IL-1β production in miR-155-/- DCs. The connection between miR-155 and inflammasome activation was supported by the fact that Nlrp3/miR-155 double knockout allo-HCT recipient mice experienced no increased protection from GvHD compared to Nlrp3-/- recipients. This study indicates that during GvHD, miR-155 promotes DC migration towards sites of ATP release accompanied by inflammasome activation. Inhibiting pro-inflammatory miR-155 by antagomir treatment could help to reduce this complication of allo-HCT.